Trends in management and healthcare resource utilization for achalasia following adoption of per-oral endoscopic myotomy

经口内镜下贲门肌切开术应用后,贲门失弛症的治疗管理和医疗资源利用趋势

阅读:2

Abstract

BACKGROUND: Per-oral endoscopic myotomy (POEM), Heller myotomy (HM), and pneumatic dilation (PD) offer definitive interventions of achalasia, but comparative analysis of long-term healthcare resource utilization is not well described. This study explores longitudinal trends and one-year post-procedure healthcare resource utilization in Indiana following local adoption of POEM in 2014. METHODS: This multicenter retrospective statewide cohort study utilized relevant ICD-9, ICD-10, and CPT codes to identify all patients with achalasia who underwent definitive index disease intervention with POEM, HM (laparoscopic HM alone or LHM with intraoperative conversion to open myotomy) or PD between January 2008 and November 2022 with ≥ 1 year follow-up. Multivariate logistic regression was utilized to determine post-intervention healthcare resource utilization. Temporizing interventions were defined as < 30 mm balloon dilation or Botox injections. RESULTS: 621 patients who underwent POEM (n = 363, mean age 54.18 years, 39% female), HM (n = 246, mean age: 48.71 years, 47% female), and PD (n = 12, mean age 52.75 years, 50% female) from two tertiary centers in Indiana were identified. From 2014 to 2022, the use of POEM increased 31-fold, while the use of HM decreased 19-fold between 2008 and 2022. Within one year of treatment, POEM was associated with less definitive reintervention compared to HM (OR 0.10, 95% CI 0.01-0.62, p = 0.01) or PD (OR 0.002, 95% CI 0.0001-0.023, p < 0.001) but more diagnostic testing than HM (OR 20.9, 95%CI 10.8, 40.4, p < 0.001). Hospital utilization within 30 days, temporizing interventions within one year, and the frequency of adverse events were similar. CONCLUSIONS: During the study period, use of POEM increased 31-fold while use of HM decreased 19-fold. POEM was associated with increased healthcare resource utilization, more post-procedure testing, lower odds of definitive disease reintervention, and similar rates of adverse events compared to HM and PD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。